Skip to content

A Response Surface Analysis for the Interaction Between Ciprofol and Sevoflurane

A Response Surface Analysis for the Interaction Between Ciprofol and Sevoflurane During Anesthesia Induction

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06773351
Enrollment
300
Registered
2025-01-14
Start date
2025-02-01
Completion date
2025-12-31
Last updated
2025-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Induction of General Anesthesia

Keywords

ciprofol, response surface analysis

Brief summary

Intravenous and inhalation combined anesthesia is a commonly used method for maintaining general anesthesia in clinical practice. This study aims to explore the interaction between ciprofol and sevoflurane. By employing response surface methodology, we constructed a three-dimensional pharmacodynamic interaction surface for various dose combinations of ciprofol and sevoflurane. This approach allows us to determine the nature of the interaction between the two drugs at any given level, thereby providing a ciprofol understanding of the dose-response relationship when ciprofol and sevoflurane are used in combination. This knowledge will serve as a theoretical basis for rational drug administration during surgery.

Interventions

DRUGCiprofol 0.4 mg/kg + different end-expiratory concentration of sevoflurane

Ciprofol 0.4 mg/kg combined with sevoflurane 0.5, 1.0, 1.5, 2.0, 2.5 %, respectively.

DRUGSevoflurane 0 + different doses of ciprofol

Sevoflurane 0% combined with ciprofol 0.1, 0.2, 0.3, 0.4, 0.6mg/kg, respectively.

DRUGSevoflurane 0.7% + different doses of ciprofol

Sevoflurane 0.7% combined with ciprofol 0.1, 0.2, 0.3, 0.4, 0.5mg/kg, respectively.

DRUGSevoflurane 1.0% + different doses of ciprofol 0.05

Sevoflurane 1.0% combined with ciprofol 0.05, 0.1, 0.2, 0.3, 0.4mg/kg, respectively.

DRUGSevoflurane 1.5% + differnet doses of ciprofol

Sevoflurane 1.5% combined with ciprofol 0.05, 0.1, 0.2, 0.3, 0.4mg/kg, respectively.

DRUGSevoflurane 2.0% + different doses of ciprofol

Sevoflurane 2.0% combined with ciprofol 0.05, 0.1, 0.15, 0.2, 0.3mg/kg, respectively.

DRUGSevoflurane 2.5% + different doses of ciprofol

Sevoflurane 2.5% combined with ciprofol 0.05, 0.1, 0.15, 0.2, 0.3mg/kg, respectively.

DRUGCiprofol 0 + different end-expiratory concentration of sevoflurane

Ciprofol 0 combined with sevoflurane 0.7, 1.5, 2.0, 2.5, 3.5%, respectively.

DRUGCiprofol 0.05mg/kg + different end-expiratory concentration of sevoflurane

Ciprofol 0.05 mg/kg combined with sevoflurane 0.7, 1.5, 2.0, 2.5, 3.5 %, respectively.

DRUGCiprofol 0.1mg/kg + different end-expiratory concentration of sevoflurane

Ciprofol 0.1mg/kg combined with sevoflurane 0.5, 1.5, 2.0, 2.5, 3.0 %, respectively.

DRUGCiprofol 0.2 mg/kg + different end-expiratory concentration of sevoflurane

Ciprofol 0.2 mg/kg combined with sevoflurane 0.5, 1.5, 2.0, 2.5, 3.0 %, respectively.

DRUGCiprofol 0.3 mg/kg + different end-expiratory concentration of sevoflurane

Ciprofol 0.3 mg/kg combined with sevoflurane 0.5, 1.0, 1.5, 2.0, 2.5 %, respectively.

Sponsors

Sichuan Provincial People's Hospital
CollaboratorOTHER
Feng Gao
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Patients undergoing elective general anesthesia and non-cardiac surgery; * Age 18-60 years old, gender is not limited; * ASA I or II level; * Body mass index (BMI) 18-30 kg/m2

Exclusion criteria

* Preoperative assessment of potential difficult airway risk; * Airway hyperreactivity; * There is disease of the central nervous system or cardiovascular system; * Currently using drugs that may alter the pharmacokinetics and pharmacokinetics of the drug under study; * Known or suspected allergy or contraindication to the components or regimens of the investigational drug; * A history of drug or alcohol addiction; * Patients with gastroesophageal reflux disease; * Severe liver and kidney dysfunction.

Design outcomes

Primary

MeasureTime frameDescription
Blood plasma concentrationInduction period of anesthesia
The score of Observer's Assessment of Alertness/Sedation ScaleInduction period of anesthesiaThe Observer's Assessment of Alertness/Sedation (OAAS) scale ranges from 1 to 5 points. 5 (awake) : The patient responds quickly to the name call with normal intonation, normal verbal answers, normal facial expressions, and bright eyes without drooping. 4 (mild sedation) : The patient is slow to respond to the name call in normal intonation, the verbal answer is slightly slow or vague, the facial expression is slightly relaxed, the eyes are glassy and the upper eyelid is slightly droopy. 3 (moderate sedation) : The patient responds only to the name call out loud, verbal responses are significantly slower or slower, facial expressions are significantly relaxed, and eyes are fixed with a visibly droopy upper eyelid. 2 (deep sedation) : The patient responds only to nudging or shaking, and the verbal response is indistinct. 1 (deep sleep, unconscious) : The patient does not respond to nudging or shaking. An OAA/S score of 2-5 is considered a response.
Numbers of of participants with laryngoscopy and tracheal intubation positive responseInduction period of anesthesiaLaryngoscopic exposure of the glottis to obtain Cormack-Lehane level 1 or 2 visual field and maintain it for 5 seconds: verbal response, eye opening, painful expression, coughing, retraction, or other purposeful or unpurposeful movements are considered responsive.
Numbers of participants with tracheal intubation stress positive resposeInduction period of anesthesiaIf the increase in heart rate (HR) or mean arterial pressure (MAP) compared to the baseline value was greater than or equal to 15% during this procedure, the stress response induced by tracheal intubation was considered to have failed to be effectively suppressed, and the effect was recorded as 1.
Bispectral Index (BIS) valueInduction period of anesthesiaThe BIS usually ranges from 0 to 100, with 0-20 indicating a state of deep anesthesia or coma; 20-40 indicates moderate anesthesia; 40-60 indicates mild anesthesia; 60-80 indicates sedation; 80-100 indicates wakefulness.

Secondary

MeasureTime frameDescription
MAPPeriod of anesthesiaThe normal range of MAP is usually 70-105 mmHg. MAP is one of the important indicators to measure the function of the human circulatory system, which represents the average arterial blood pressure in a cardiac cycle. During anesthesia, MSP less than 20% of baseline is considered hypotensive.
Adverse reactionsPerioperative period
HRPeriod of anesthesiaFor adults, the normal heart rate range is usually between 60 and 100 beats per minute. During anesthesia, HR less than 20% of baseline is considered hypotensive

Contacts

Primary ContactFeng Gao, PhD
fgao@tjh.tjmu.edu.cn+86 13971587381

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026